Inhibition of VEGFR3 signaling has been shown to reduce metastasis of cancer in multiple murine models, including lung, colorectal, and breast cancer [14–19] and anti-VEGFR3 monoclonal antibodies are currently in early phase clinical trials for solid tumors (NCT01288989). This evidence concerns the gene FLT4 and breast cancer.